Skip to main content
Premium Trial:

Request an Annual Quote

Dutch Biomarker Firm ACS Biomarker Closes Financing, Appoints New CEO

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ACS Biomarker reported on Friday it has closed on a financing round and appointed a new CEO.

The amount of the funding was not disclosed. In a statement, the company, based in Maastricht, Netherlands, said it will be used to further develop its product pipeline and discover novel biomarkers "that improve diagnosis, prognosis, and management of cardiac diseases."

Funding came from Life Sciences Fund Amsterdam and Limburg Ventures, ACS said.

ACS Biomarker, spun out of Maastricht University Medical Centre in 2007, recently established an office and research facility in Amsterdam. Its R&D is focused on miRNA- and protein-based cardiovascular biomarkers.

Its first protein biomarker, galectin-3, was licensed to BG Medicine, whose test for heart failure based on the biomarker was cleared by the US Food and Drug Administration in November.

The company also said it has appointed a new CEO, Heico Breek, who said in a statement that his main objective will be on the expansion and commercialization of ACS Biomarker's portfolio.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more